S
Silvia Montestruque
Researcher at Amgen
Publications - 5
Citations - 596
Silvia Montestruque is an academic researcher from Amgen. The author has contributed to research in topics: CD22 & Internalization. The author has an hindex of 5, co-authored 5 publications receiving 578 citations.
Papers
More filters
Journal ArticleDOI
AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts.
Anthony Polverino,Angela Coxon,Charlie Starnes,Zobedia Diaz,Thomas DeMelfi,Ling Wang,James Bready,Juan Estrada,Russell C. Cattley,Stephen J. Kaufman,Danlin Chen,Yongmei Gan,Gondi N. Kumar,James Meyer,Sesha Neervannan,Gonzalo Alva,Jane Talvenheimo,Silvia Montestruque,Andrew Tasker,Vinod F. Patel,Robert Radinsky,Richard Kendall +21 more
TL;DR: Oral administration of AMG 706 potently inhibited VEGF-induced angiogenesis in the rat corneal model and induced regression of established A431 xenografts and had no significant effects on body weight or on the general health of the animals.
Journal Article
Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties.
Josette Carnahan,Paul Wang,Richard Kendall,C. Q. Chen,Sylvia Hu,Tom Boone,Todd Juan,Jane Talvenheimo,Silvia Montestruque,Jilin Sun,Gary Elliott,John C. Thomas,John Ferbas,Brent Kern,Robert A. Briddell,John P. Leonard,Alessandra Cesano +16 more
TL;DR: Epratuzumab represents an excellent anti-CD22 ligating agent, highly efficacious in inducing CD22 internalization, and can induce phosphorylation, which are the fundamental characteristics of the target CD22 and its interaction with epratzumab.
Journal ArticleDOI
Interactions between brain-derived neurotrophic factor and the TRKB receptor. Identification of two ligand binding domains in soluble TRKB by affinity separation and chemical cross-linking.
Mitsuru Haniu,Silvia Montestruque,Edward J. Bures,Jane Talvenheimo,Robert J. Toso,Stephanie Lewis-Sandy,Andrew A. Welcher,Michael F. Rohde +7 more
TL;DR: Two distinct ligand binding domains of TRKB were isolated from proteolytic digests of the receptor by affinity separation on immobilized BDNF, indicating the importance of two distinct regions of the extracellular domain of the TRKB receptor in binding BDNF.
Journal ArticleDOI
Recombinant rat fibroblast growth factor-16: structure and biological activity.
Dimitry M. Danilenko,Silvia Montestruque,John S. Philo,Tiansheng Li,David C. Hill,Jamie Speakman,Menbere Bahru,Maosheng Zhang,Morichika Konishi,Nobuyuki Itoh,Madaline Chirica,John M. Delaney,Natasha Hernday,Frank Martin,Shinichi Hara,Jane Talvenheimo,Linda O. Narhi,Tsutomu Arakawa +17 more
TL;DR: It is shown that d34 rFGF-16 induces oligodendrocyte proliferation in vitro, and induces hepatocellular proliferation and increased liver weight in vivo.
Journal Article
Epratuzumab, a Humanized Monoclonal Antibody Targeting CD22
Josette Carnahan,Paul Wang,Richard Kendall,C. Q. Chen,Sylvia Hu,Tom Boone,Todd Juan,Jane Talvenheimo,Silvia Montestruque,Jilin Sun,Gary Elliott,John C. Thomas,John Ferbas,Brent Kern,Robert A. Briddell,John P. Leonard,Alessandra Cesano +16 more
TL;DR: Epratuzumab represents an excellent anti-CD22 ligating agent, highly efficacious in inducing CD22 internalization, and can induce phosphorylation, which are the fundamental characteristics of the target CD22 and its interaction with epratzumab.